Bharat Parenterals Share Price

	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025
Total Income	103.25	66.52	68.15	117.06	105.90
Total Income Growth (%)	55.23	-2.40	-41.78	10.54	40.82
Total Expenses	108.78	71.90	72.35	110.82	110.26
Total Expenses Growth (%)	51.29	-0.62	-34.71	0.51	42.49
EBIT	-5.53	-5.39	-4.20	6.24	-4.36
EBIT Growth (%)	-	-	-167.31	-	-
Profit after Tax (PAT)	-4.80	-4.39	-7.23	8.23	-4.73
PAT Growth (%)	-	-	-187.85	-	-
EBIT Margin (%)	-5.35	-8.10	-6.16	5.33	-4.12
Net Profit Margin (%)	-4.64	-6.59	-10.61	7.03	-4.47
Basic EPS (₹)	-11.84	-14.03	-14.00	-1.27	-14.40

	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025
Total Income	60.98	43.69	45.91	95.99	82.54
Total Income Growth (%)	39.58	-4.84	-52.17	16.30	16.04
Total Expenses	58.54	40.04	41.53	81.17	77.50
Total Expenses Growth (%)	46.19	-3.58	-48.84	4.74	27.34
EBIT	2.44	3.65	4.38	14.82	5.04
EBIT Growth (%)	-33.04	-16.78	-70.45	194.05	-50.93
Profit after Tax (PAT)	1.38	1.92	2.73	10.00	2.28
PAT Growth (%)	-28.12	-29.84	-72.70	338.60	-64.92
EBIT Margin (%)	4.00	8.34	9.54	15.44	6.11
Net Profit Margin (%)	2.26	4.38	5.95	10.42	2.76
Basic EPS (₹)	2.00	2.78	3.96	14.51	3.48

	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Revenue	354.98	352.00	265.95	229.72	219.79
Total Revenue Growth (%)	0.85	32.35	15.77	4.52	3.03
Total Expenses	376.40	385.95	247.23	206.17	191.92
Total Expenses Growth (%)	-2.47	56.11	19.92	7.43	3.07
Profit after Tax (PAT)	-8.19	-12.63	14.52	16.44	21.05
PAT Growth (%)	-	-186.97	-11.70	-21.91	3.25
Operating Profit Margin (%)	-2.57	-6.16	8.52	11.80	13.57
Net Profit Margin (%)	-2.37	-3.70	5.64	7.54	9.92
Basic EPS (₹)	-39.62	-66.64	24.94	28.40	36.67

	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Revenue	246.57	318.68	266.11	236.82	219.79
Total Revenue Growth (%)	-22.63	19.75	12.37	7.75	3.51
Total Expenses	224.72	282.37	235.31	204.65	191.42
Total Expenses Growth (%)	-20.41	20.00	14.98	6.91	3.29
Profit after Tax (PAT)	16.02	26.45	22.59	24.34	21.30
PAT Growth (%)	-39.45	17.08	-7.16	14.24	5.41
Operating Profit Margin (%)	10.80	13.51	13.37	15.76	13.80
Net Profit Margin (%)	6.84	8.69	8.88	11.16	10.04
Basic EPS (₹)	23.24	40.36	38.81	42.14	37.11

All figures in Rs Cr, unless mentioned otherwise

Insights

Quarterly Topline Performance
Company witnessed QoQ revenue growth of 55.23%, which is highest in the last 3 years. (Source: Consolidated Financials)
Employee & Interest Expense
Company has spent 3.63% of its operating revenues towards interest expenses and 19.48% towards employee cost in the year ending Mar 31, 2026. (Source: Consolidated Financials)

View Details

Balance Sheet

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Assets	613.30	648.53	503.82	350.34	226.06
Total Assets Growth (%)	-5.43	28.72	43.81	54.98	13.80
Total Liabilities	301.72	309.53	265.65	132.45	55.91
Total Liabilities Growth (%)	-2.53	16.52	100.57	136.88	1.97
Total Equity	311.58	339.00	238.17	217.89	170.14
Total Equity Growth (%)	-8.09	42.33	9.31	28.06	18.30
Current Ratio (x)	1.99	1.62	1.37	1.54	3.46
Total Debt to Equity (x)	0.45	0.54	0.80	0.27	0.11
Contingent Liabilities	0.00	72.15	41.13	75.15	48.30

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Assets	519.94	549.19	387.15	308.03	218.00
Total Assets Growth (%)	-5.33	41.85	25.69	41.30	11.09
Total Liabilities	117.60	162.36	173.54	116.97	51.85
Total Liabilities Growth (%)	-27.57	-6.44	48.36	125.59	-0.84
Total Equity	402.34	386.83	213.61	191.06	166.15
Total Equity Growth (%)	4.01	81.09	11.80	14.99	15.43
Current Ratio (x)	2.16	1.72	1.30	1.61	3.57
Total Debt to Equity (x)	0.05	0.17	0.39	0.24	0.09
Contingent Liabilities	0.00	51.47	25.68	27.50	24.46

All figures in Rs Cr, unless mentioned otherwise

View Details

Cash Flows

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Net Cash flow from Operating Activities	38.36	-27.25	-4.71	21.66	-1.07
Net Cash used in Investing Activities	9.32	-137.39	-104.78	-77.82	-6.63
Net Cash flow from Financing Activities	-47.05	156.37	110.43	60.60	9.42
Net Cash Flow	0.64	-8.27	0.94	4.44	1.72
Closing Cash & Cash Equivalent	1.20	0.44	8.78	7.84	3.40
Closing Cash & Cash Equivalent Growth (%)	170.28	-94.96	11.98	130.68	102.70
Total Debt/ CFO (x)	3.81	-6.61	-33.49	2.30	-16.65

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Net Cash flow from Operating Activities	44.57	19.22	-22.92	-11.56	-22.15
Net Cash used in Investing Activities	4.14	-89.69	-16.10	-13.95	21.76
Net Cash flow from Financing Activities	-48.80	69.25	34.17	28.52	2.32
Net Cash Flow	-0.10	-1.21	-4.84	3.01	1.93
Closing Cash & Cash Equivalent	0.24	0.22	1.50	6.34	3.33
Closing Cash & Cash Equivalent Growth (%)	9.60	-85.41	-76.36	90.56	137.47
Total Debt/ CFO (x)	0.45	3.37	-3.62	-3.95	-0.68

All figures in Rs Cr, unless mentioned otherwise

View Details

Ratios

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Return on Equity (%)	-2.54	-3.81	7.35	8.99	12.69
Return on Capital Employed (%)	-1.94	-4.89	7.00	11.16	15.59
Return on Assets (%)	-1.33	-1.94	2.88	4.69	9.31
Interest Coverage Ratio (x)	2.02	1.11	9.60	14.44	39.64
Asset Turnover Ratio (x)	0.55	0.59	0.60	0.76	1.02
Price to Earnings (x)	-76.34	-54.05	45.05	11.81	9.37
Price to Book (x)	1.93	2.06	3.31	1.06	1.19
EV/EBITDA (x)	29.33	56.66	27.11	8.50	6.05
EBITDA Margin (%)	7.34	4.20	12.03	14.50	16.71

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Return on Equity (%)	3.98	6.83	10.57	12.73	12.82
Return on Capital Employed (%)	6.04	10.41	15.49	17.20	16.45
Return on Assets (%)	3.08	4.81	5.83	7.90	9.77
Interest Coverage Ratio (x)	9.79	10.06	12.67	18.39	40.19
Asset Turnover Ratio (x)	0.44	0.65	0.73	0.83	1.02
Price to Earnings (x)	38.76	25.77	28.99	7.97	9.26
Price to Book (x)	1.54	1.76	3.06	1.02	1.19
EV/EBITDA (x)	18.82	14.90	18.16	5.78	5.78
EBITDA Margin (%)	14.37	15.83	15.89	18.44	16.94

Found Financials useful?

5 Days	14 Days	28 Days
-	-	-

Peer Comparison

Ratio Performance

NAME	P/E (x)	P/B (x)	ROE %	ROCE %	ROA %	Rev CAGR [3Yr]	OPM	NPM	Basic EPS	Current Ratio	Total Debt/ Equity (x)	Total Debt/ CFO (x)
Bharat Parenterals	-112.88	2.96	-2.54	-1.94	-1.33	15.44	-2.57	-7.90	-39.62	1.99	0.45	3.81
Fermenta Biotech	14.77	2.68	17.86	22.88	11.20	15.11	19.13	13.37	24.70	1.86	0.27	1.17
Themis Medicare	917.86	2.63	0.28	-0.13	0.19	-1.30	-0.16	-3.77	0.12	1.84	0.25	-30.65
Bajaj Healthcare	64.57	1.91	2.95	14.28	1.70	-2.86	13.81	2.58	4.98	1.92	0.44	4.02
Wanbury Ltd	14.61	16.30	51.50	27.78	7.37	9.07	11.09	5.09	9.32	1.11	2.92	6.64
Add More

Annual Ratios (%)

Choose from Peers

Kopran Ltd
Anuh Pharma
Vikram Thermo
Zim Laboratories
Praveg Comm

Choose from Stocks

Stock Performance

CHART
TABLE

1D
1W
1M
3M
6M
1Y
5Y

Choose from Peers
Choose from Stocks

NAME	1D	1W	1M	3M	1Y	3Y	5Y
Bharat Parenterals Stock Performance	1.07	10.30	10.47	21.76	19.97	308.41	246.34
Fermenta Biotech Stock Performance	-0.26	25.06	15.80	12.68	23.89	148.97	17.42
Themis Medicare Stock Performance	-3.59	15.82	23.38	27.39	-20.22	-27.24	130.54
Bajaj Healthcare Stock Performance	-2.90	3.10	-8.07	-14.02	-46.12	-0.84	2.27
Wanbury Ltd Stock Performance	-1.37	7.86	7.30	2.58	-3.99	480.05	166.59
Add More

Category	No. of Shares	Percentage	% Change QoQ
Promoters	46,29,330	67.17 %	-0.01
Pledge	0	0.00 %	0.00
FII	7,500	0.11 %	0.00
DII	72,862	1.06 %	0.53
Others	21,82,271	31.65 %	-0.51

Category	Mar 2026	Dec 2025	Sep 2025	Jun 2025
Promoters	67.17	67.19	67.19	67.19
Pledge	0.00	0.00	0.00	0.00
FII	0.11	0.11	0.11	0.11
DII	1.06	0.53	0.53	0.53
Mutual Funds	0.00	0.00	0.00	0.00
Others	31.65	32.17	32.17	32.17

Mutual Funds Ownership

No Data Available

Corporate Actions

Recent
Final
10%
May 18, 2026
Board Meeting
Audited Results & Final Dividend
May 11, 2026
Board Meeting
Quarterly Results
Jan 22, 2026

Board Meetings

Announced on	Meeting on
May 11, 2026	May 18, 2026
Audited Results & Final Dividend
Jan 22, 2026	Jan 30, 2026
Quarterly Results
Nov 06, 2025	Nov 12, 2025
Quarterly Results
Jul 22, 2025	Jul 28, 2025
Quarterly Results & A.G.M.
May 05, 2025	May 12, 2025
Audited Results & Final Dividend

Dividends
Announced on Ex-Date Dividend%
May 12, 2025 Sep 19, 2025 10%
Jun 10, 2024 Jun 25, 2024 10%
May 22, 2023 Sep 25, 2023 7%
May 18, 2026 - 10%
Aug 11, 2001 - 0%
Bonus
No Data Available
Splits
No Data Available
Rights
No Data Available
AGM/EGM Meetings
Announced on Meeting on
Sep 04, 2025 Sep 26, 2025
-
Sep 06, 2024 Oct 07, 2024
-
Jun 10, 2024 Jul 02, 2024
-
Sep 08, 2023 Sep 30, 2023
A.G.M.
Sep 17, 2020 Sep 30, 2020
-

Announced on	Ex-Date	Dividend%
May 12, 2025	Sep 19, 2025	10%
Jun 10, 2024	Jun 25, 2024	10%
May 22, 2023	Sep 25, 2023	7%
May 18, 2026	-	10%
Aug 11, 2001	-	0%

Announced on	Meeting on
Sep 04, 2025	Sep 26, 2025
-
Sep 06, 2024	Oct 07, 2024
-
Jun 10, 2024	Jul 02, 2024
-
Sep 08, 2023	Sep 30, 2023
A.G.M.
Sep 17, 2020	Sep 30, 2020
-

About Bharat Parenterals

Bharat Parenterals Ltd., incorporated in the year 1992, is a Small Cap company (having a market cap of Rs 923.52 Crore) operating in Pharmaceuticals sector.

Bharat Parenterals Ltd. key Products/Revenue Segments include Pharmaceuticals, Export Incentives, Other Operating Revenue and Scrap for the year ending 31-Mar-2025.

For the quarter ended 31-03-2026, the company has reported a Consolidated Total Income of Rs 103.25 Crore, up 55.23 % from last quarter Total Income of Rs 66.52 Crore and down 2.50 % from last year same quarter Total Income of Rs 105.90 Crore. Company has reported net profit after tax of Rs -8.16 Crore in latest quarter.

The company’s top management includes Mr.Bharat R Desai, Mr.Hemang J Shah, Mr.Alkesh Shah, Mr.Mukesh Patel, Mr.Shailesh Gabhawala, Mrs.Zankhana Sheth, Mr.Jignesh Shah, Mr.Sharmin N Soni. Company has Shah Mehta & Bakshi as its auditors. As on 31-03-2026, the company has a total of .69 Crore shares outstanding.

Bharat Parenterals Share Price Today is Rs. 1340.00. On previous day, the Bharat Parenterals Share Price (NSE) closed at Rs. 1325.7, featuring among the most traded securities on the National Stock Exchange.

Shareholdings:
As of 31st Mar, 2026, the promoter held 67.17% of the stake in Bharat Parenterals shares, out of which 0.0% was pledged. On the same date, foreign institutional investors' (FII) holdings of Bharat Parenterals stocks was 0.11% as compared to 0.11% in Dec 2025 with decrease of 0.0%. The domestic institutional investors (DII) holdings on 31st Mar, 2026 was 1.06% as compared to 0.53% in Dec 2025 with increase of 0.53%. Out of the total DII holdings in Bharat Parenterals shares 0.0% was held by mutual funds. The rest including public held is 31.66%. Bharat Parenterals stock price is reflected on both the exchanges - BSE and NSE.

Dividend, Bonus & Split Information:
Bharat Parenterals Dividend: Ever since 1992, Bharat Parenterals dividends has been paid out around 5 times. As on 25 Jun, 2026, 03:40 PM IST, The overall dividend yield for Bharat Parenterals stands at 0.07%. The last dividend paid was on September 19, 2025 (Rs. 1.0). The Earnings Per Share (EPS) for quarter ending 31st Mar 2026 is Rs. -11.87.

Bharat Parenterals Bonus: The most recent bonus issue had been in year null around 0 years ago at 0 : 0 ratio. The first bonus issue was announced in null.

Stock Forecast:
After showing 103.25 Cr. of sales and 55.23% of quarterly net profit, there have been multiple ups and downs in the Bharat Parenterals stock prices in the past few weeks. For example, Bharat Parenterals stock price on 19th of June 2026 was around Rs. 1311.3. Bharat Parenterals share price now stands at an average of Rs. 1340.00. Judging by last week's performance, stock is in up trend.

Bharat Parenterals has a median target price of Rs. 0.0 in 12 months by 0 analysts. They have provided a high estimate of Rs. 0.0 and low estimate of Rs. 0.0 for Bharat Parenterals share.

Historical Prices and Performance:
Bharat Parenterals, incorporated in 1992 is a Small Cap company (with a market cap of Rs. 923.52) operating in Pharmaceuticals sector.
The Return of Equity (ROE) in last five financial years given by Bharat Parenterals stock was -2.54%, -3.81%, 7.35%, 8.99% and 12.69% respectively.
The Bharat Parenterals share gave a 3 year return of 248.05% as compared to Nifty 50 which gave a return of 28.88%.
Bharat Parenterals announced 10.0% final dividend on September 19, 2025.

Key Metrics:
PE Ratio of Bharat Parenterals is -112.88
Prices/Sales Ratio of Bharat Parenterals is 1.8
Price/Book Ratio of Bharat Parenterals is 2.96

Peer Insights:
Peers are businesses with comparable activities, buisness objectives and affiliation with a particular industry area. The PE ratio and PB Ratio of the company are among its competitors stand at -112.88 and 2.96 respectively.

Leadership of Bharat Parenterals :
Sharmin N Soni is Co. Secretary & Compl. Officer
Jignesh Shah is Chief Financial Officer
Bharat R Desai is Managing Director
Hemang J Shah is Executive Director
Mukesh Patel is Independent Director
Zankhana Sheth is Independent Director
Shailesh Gabhawala is Independent Director
Alkesh Shah is Non Exe.Non Ind.Director

Industry

Pharma - Indian

Key Indices Listed On

-

Address

Survey No. 144-A,Jarod- Samlaya Road,Village Haripura, Taluka Savli,Vadodra District, Gujarat - 391520

Contact

info@bplindia.in

http://www.bplindia.in

PE Ratio(x)	-112.88
EPS - TTM(₹)	-11.87
MCap(₹ Cr.)	923.52
MCap Rank	93
PB Ratio(x)	2.93
Div Yield(%)	0.07
Face Value(₹)	10.00
52W High(₹)	1,667.20
52W Low(₹)	880.25
MCap/Sales	1.80
Beta(1 Month)	-0.18
BV/Share(₹)	452.09

1 Day	1.07%
1 Month	2.02%
3 Months	35.09%
1 Year	21.82%
3 Years	262.16%
5 Years	262.46%

R1	-	Pivot -	S1	-
R2	-		S2	-
R3	-		S3	-

Bharat Parenterals Share Price

Key Metrics